RecruitingNCT05200429

Canadian Observational Study Evaluating the Long-term IMPACT of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators on People With CF

Canadian Observational Study Evaluating the Long-term IMPACT of CFTR (Can-IMPACT CF)


Sponsor

University of British Columbia

Enrollment

500 participants

Start Date

Nov 1, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

This observational study intends to investigate health trends and data in cystic fibrosis patients all across Canada that are receiving modulator treatment so researchers can determine if CFTR treatments are effective over a long period of time and if so, which treatments work best for each individual. The study will collect clinical data from routine standard of care, patient reported outcomes via survey data and samples for a biobank.


Eligibility

Inclusion Criteria3

  • Prescribed a CFTR modulator therapy and planning to commence modulator therapy within 30 days OR planning to switch modulator therapies within 30 days
  • Participates in the Canadian Cystic Fibrosis Registry (CCFR)
  • Informed consent by participant, or parent/legal guardian or assent

Exclusion Criteria1

  • Known contraindications to CFTR modulator therapy

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTrikafta

Highly Effective CFTR Modulator Therapy


Locations(2)

British Columbia Children's Hospital

Vancouver, British Columbia, Canada

St Paul's Hospital

Vancouver, British Columbia, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05200429


Related Trials